99.9% effectiveness: new type of treatment for HIV/AIDS has received the green light

The FDA has approved a generic version of lenacapavir for HIV/AIDS prevention, announced by Dr. Reddy’s Laboratories and Unitaid. This injectable treatment aims to improve access to affordable HIV prevention, addressing urgent global needs. Originally developed by Gilead, lenacapavir will be available in 120 countries at an annual cost of $40 per person. The treatment involves two injections per year, significantly reducing the risk of HIV transmission. This breakthrough offers hope for decreasing new infections, particularly in developing nations.